Back to Platforms

Platform 7: Randomised Control Trials

In many low- and middle-income country settings, even after vector control products have regulatory approval, they need to be on a WHO recommended list before donors will make large scale purchases. This often requires large scale epidemiological impact trials, ideally in contrasting transmission settings, that are beyond the budgets of the manufacturers. This can lead to long delays in roll out of potentially-effective new products.

iiCON is pioneering pioneered model systems to embed cluster-randomised control trials into large-scale operational programmes, through which it can be demonstrated whether the products are as good as or better than the current recommended products. By reducing the cost and complexity of these operationally-embedded trials and providing key data-led-insight to a broad range of organisations including non-governmental organisations, governments, and non-profit organisations, iiCON provides expertise to support and inform global health policy decisions.

Led by an expert team at Liverpool School of Tropical Medicine, this platform provides robust data to inform global health policy and supports and enables market access, helping to protect communities from diseases including malaria.

This work is already helping to protect communities and save lives by advancing innovative interventions.

For more information or to learn how your business can engage with this platform.

Email Dr Becky Jones-Phillips

Dr David Weetman

Platform Lead

Dr David Weetman

Reader, Liverpool School of Tropical Medicine

Dr Weetman graduated in Zoology (BSc) from the University of Newcastle-upon-Tyne and in Ecology (MSc) from The University of Wales, Bangor. His PhD at The University of Liverpool was followed by postdoctoral positions in the Molecular Ecology and Fisheries Genetics Group at the University of Hull.

Read more

Learn more about collaborating with iiCON

Discover more